Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
This study not only corroborates previously established risks associated with cladribine but also uncovers new potential safety signals, highlighting the importance of vigilance for early acute toxicity.
Authors
- Yu‐Wen Hu (ORCID: https://orcid.org/0000-0002-7983-415X)
- Qiong Yao (ORCID: https://orcid.org/0000-0002-1021-3208)
- Jun Yong He (ORCID: https://orcid.org/0000-0001-8056-0347)
- Zhijun Jin (ORCID: https://orcid.org/0000-0001-9739-981X)
- Hongyu Ye (ORCID: https://orcid.org/0009-0008-0360-8974)
- Yanyan Zheng (ORCID: https://orcid.org/0000-0002-7797-7229)
- Yunhan Zhao (ORCID: https://orcid.org/0000-0002-3002-8296)
- Haoxiang Hu
- Caixiang Zhuang
- Zhengkai Tu (ORCID: https://orcid.org/0000-0002-0388-533X)
Institutions
- Wenzhou Medical University (CN)
- Wenzhou City People's Hospital (CN)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2025-11-15
- DOI
- https://doi.org/10.1007/s11096-025-02041-8
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Natural Science Foundation of Zhejiang Province